N-(Phenoxyalkyl)amides as MT1 and MT2 ligands: Antioxidant properties and inhibition of Ca2+/CaM-dependent kinase II by A. Carocci et al.
Bioorganic & Medicinal Chemistry 21 (2013) 847–851Contents lists available at SciVerse ScienceDirect
Bioorganic & Medicinal Chemistry
journal homepage: www.elsevier .com/locate /bmcN-(Phenoxyalkyl)amides as MT1 and MT2 ligands: Antioxidant
properties and inhibition of Ca2+/CaM-dependent kinase II0968-0896/$ - see front matter  2012 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.bmc.2012.12.017
⇑ Corresponding author. Tel.: +39 080 5442745; fax: +39 080 5442724.
E-mail address: alessia.carocci@uniba.it (A. Carocci).Alessia Carocci a,⇑, Alessia Catalano a, Claudio Bruno a, Angelo Lovece a, Maria Grazia Roselli a,
Maria Maddalena Cavalluzzi a, Francesco De Santis b, Annalisa De Palma b, Maria Rosaria Rusciano c,
Maddalena Illario c, Carlo Franchini a, Giovanni Lentini a
aDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ‘Aldo Moro’, Via E. Orabona 4, 70125 Bari, Italy
bDipartimento di Bioscienze, Biotecnologie e Biofarmaceutica, Università degli Studi di Bari ‘Aldo Moro’, Via Orabona 4, 70125 Bari, Italy
cDipartimento di Biologia e Patologia Cellulare e Molecolare, Università Federico II, 80131 Napoli, Italy
a r t i c l e i n f oArticle history:
Received 25 September 2012
Revised 12 December 2012
Accepted 16 December 2012





DCFH-DAa b s t r a c t
Recently a series of chiral N-(phenoxyalkyl)amides have been reported as potent MT1 and MT2 melaton-
ergic ligands. Some of these compounds were selected and tested for their antioxidant properties by mea-
suring their reducing effect against oxidation of 20 ,70-dichlorodihydroﬂuorescein (DCFH) in the DCFH-
diacetate (DCFH-DA) assay. Among the tested compounds, N-[2-(3-methoxyphenoxy)propyl]butanamide
displayed potent antioxidant activity that was stereoselective, the (R)-enantiomer performing as the
eutomer. This compound displayed strong cytoprotective activity against H2O2-induced cytotoxicity
resulting slightly more active than melatonin, and performed as Ca2+/calmodulin-dependent kinase II
(CaMKII) inhibitor, too.
 2012 Elsevier Ltd. All rights reserved.1. Introduction
Melatonin (MLT, 1, Fig. 1) is a tryptophan derivative primarily
produced by the pineal gland with a marked circadian rhythm that
is governed by the central circadian pacemaker in the suprachias-
matic nuclei of the hypothalamus, the highest levels occurring dur-
ing the period of darkness.1 This hormone regulates and modulates
a wide variety of physiological functions. Besides the well-known
chronobiotic and sleep inducing properties,2 many other physio-
logical effects have been ascribed to MLT, such as the modulation
of cardiovascular3 and immune4 systems and the inﬂuence on hor-
mone secretion and metabolism.5 Other effects of MLT described in
the literature include antitumor,6,7 anti-inﬂammatory,8 pain mod-
ulator,9 neuroprotective,10,11 and antioxidant12 properties. MLT ex-
erts its actions by multiple mechanisms. Many of its physiological
actions are mediated through G-protein coupled receptors ex-
pressed in a wide variety of tissues. Cloning studies have revealed
at least three MLT receptor subtypes, two of which (MT1 and MT2)
have been found in mammals,13,14 and are localized in different
areas of the central nervous system as well as in peripheral tis-
sues.15,16 Moreover, a non-mammalian MLT binding site with a
lower afﬁnity proﬁle (MT3) has been found in hamster brain and
characterized as a MLT-sensitive form of the human enzyme qui-none reductase 2.17 Many in vitro and in vivo experimental models
have contributed to demonstrate the role of MLT as an efﬁcient
radical scavenger against several reactive oxygen species (ROS),
for example, the hydroxyl radical, the peroxynitrite anion, the
superoxide anion, and singlet oxygen.18,19 MLT has also been
shown to enhance the production and the activity of several anti-
oxidant enzymes, including superoxide dismutase, glutathione
peroxidase, glutathione reductase, catalase, and glucose-6-phos-
phate dehydrogenase.20,21 Furthermore, in vivo observations on
the protective role of MLT in ischemic brain injury22 or in animal
models of Alzheimer’s disease23 emphasize the therapeutic poten-
tial of this compound as a neuroprotective agent.24 Nevertheless,
the potential application of MLT in an antioxidant therapy could
be complicated by the pharmacokinetic behaviour of the molecule,
which is subjected to a considerable ﬁrst-pass effect and to a lim-
ited bioavailability and plasma half life after oral administration.25
Thus, the availability of new compounds sharing the beneﬁcial
properties of MLT, but presenting different pharmacokinetic pro-
ﬁles could therefore be envisaged. During the past two decades, a
great number of structurally different MLT receptor ligands have
been reported in the literature.26–29 Several melatonin-related
compounds such as melatonin metabolites and synthetic ana-
logues have been under investigation as antioxidants, most of
them being indole-based compounds.30,31 Recently, basing on the
results obtained on a series of N-phenylalkyl amides by Garratt
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Figure 1. Set of compounds included in the study.
Table 1
MT1 and MT2 melatonin receptors afﬁnities and antioxidant potencies in the DCFH-
DA assay for MLT and the set of compounds under study
Compounds pKia DCFH-DAb
MT1 MT2 IC50 ± SEM (lM)
MLT 9.48 9.21 271.0 ± 0.1
2 8.44 8.02 >1000
3 8.38 8.43 226.4 ± 0.1
(R)-3 7.09 7.17 182.9 ± 0.2
(S)-3 8.51 8.56 >1000
4 9.03 7.89 >1000
5 4.94 5.26 >1000
6 4.92 5.42 >1000
7 5.86 5.94 >1000
a Ref. 33.
b Values are the mean of at least three determinations performed in sextuplicate.
Table 2
Effect of different concentrations (0.1–5.5 mM) of compounds 3, (R)-3, (S)-3, and MLT
on their interaction with DPPH (100 lM)
Compounds Percentage of Interaction with DPPHa
0.1 mM 1mM 5.5 mM IC50 (lM)
3 3.22 ± 0.24 4.05 ± 0.19 11.7 ± 0.4 ndb
(R)-3 5.60 ± 0.25 5.10 ± 0.90 20.7 ± 1.00 ndb
(S)-3 2.80 ± 0.70 1.30 ± 1.00 15.1 ± 0.9 ndb
MLT 2.10 ± 0.70 7.80 ± 0.50 31.8 ± 0.3c ndb
Gallic acid 97.14 ± 0.03 ndb ndb 6.0 ± 0.3d
a Values are the mean of at least three determinations performed in
quadruplicate.
b nd: not determined.
c Literature value: 40%.39
d Literature value: 1.83 ± 0.17 lM.45
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relationship (SAR) study around the terminal amide moiety, the al-
kyl chain, and the methoxy group on the aromatic ring provided
compounds with nanomolar afﬁnity for both melatonin receptor
subtypes. In the present study we investigated some of these com-
pounds (2–7, Fig. 1) as antioxidants. Furthermore, the ability of
MLT to inhibit in vitro Ca2+/calmodulin-dependent kinase II (CaM-
KII) activity at physiological concentrations has been reported.34
CaMKII is particularly abundant in the nervous system where it
is involved in a series of important patho-physiological processes
because of its ability to phosphorylate a broad spectrum of sub-
strates.35–37 Despite its pharmacological signiﬁcance, a complete
characterization of the interaction between MLT and CaMKII is still
lacking. Both antioxidant and CaMKII inhibiting properties might
prove beneﬁcial to neurodegenerative disorders.38 Herein we
decided to investigate the potential CaMKII inhibitory effect of
our best melatonergic ligands (3,4) and MLT (1).
2. Results
The in vitro antioxidant activity of a series of melatonergic li-
gands (Fig. 1) was evaluated by means of the 20,70-dichlorodihydro-
ﬂuorescein diacetate (DCFH-DA) cellular-based assay by
measuring the reducing effect of the test compounds against oxi-
dation of 20,70-dichlorodihydroﬂuorescein (DCFH) to the ﬂuores-
cent probe 20,70-dichloroﬂuorescein (DCF) The set of compounds
was constructed by selecting a series of N-(phenoxyalkyl)amides
previously reported as MLT receptor ligands.33 As shown in Table 1,
the selected compounds are characterized by different afﬁnities for
MLT receptors with Ki values spanning four orders of magnitude.33
We tested MLT receptor ligands with high afﬁnity (2–4) and three
compounds that behave as poor melatonergic ligands (5–7). These
compounds were compared with MLT (1) which was chosen as the
reference compound. Tests were performed on human hepatocel-
lular liver carcinoma (HepG2) cells because they have an enhanced
oxidative metabolism that causes cellular oxidative stress and/or
generates reactive metabolites. Thus it may be assumed that
HepG2 cells are suited to study protection against oxidative and
cytotoxic effects, if any. The results of the DCFH-DA assay showed
that only compound 3 signiﬁcantly reduces the H2O2-induced oxi-
dation, being slightly more potent than MLT. Tests carried out on
the homochiral forms of 3 revealed a difference between the enan-
tiomers being the (R)-isomer the eutomer. Then, in order to evalu-
ate the potential efﬁcacy as scavenger of stable free radicals, MLT
and compounds 3, (R)-3, and (S)-3 were analyzed by observingthe reactivity with 1,1-diphenyl-2-picrylhydrazyl (DPPH), a vio-
let-coloured stable radical that absorbs strongly at 517 nm. The ef-
fect of three different concentrations (0.1–5.5 mM) of the tested
compounds on their interaction with DPPH (100 lM) is shown in
Table 2. Experiments were performed also with gallic acid, a natu-
rally occurring plant phenol with antioxidative activity, as the ref-
erence substance. In agreement with what was reported in the
literature,39 MLT showed low reactivity with this radical. At a con-
centration of 5.5 mM the compound decreases DPPH absorption by
only 31.8%. The same behaviour was observed for compounds 3,
(R)-3, and (S)-3 that slightly scavenged the level of DPPH radical
Figure 2. Cell viability in the absence of H2O2 (control, white histogram), in the
presence of 125 lg/mL H2O2 (black histogram), and with H2O2 (125 lg/mL) and
increasing concentrations of 3 (light gray), (R)-3 (gray), or MLT (dark gray). No
viability variation was obtained with (S)-3 in the range of concentrations observed
(10100 lg/mL). Viability is expressed in percent of the number of the control
viable cells; n = 3 independent experiments; mean ± SEM presented; ^P <0.1, ⁄P
<0.05, ⁄⁄P <0.01 versus H2O2 treated cells.
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tively. Then, the cytoprotective effect of MLT, compound 3 and its
(R)-enantiomer, was evaluated against H2O2-induced cytotoxicity
(Fig. 2) on HepG2 cells. Compared with MLT, both 3 and (R)-3
showed higher cytoprotective activity when tested at concentra-
tions close to their IC50 values. In particular, compound (R)-3
showed a more pronounced action, with percentage of cell viability
close to 100% at the concentration of 100 lg/mL. As far as the inhi-
bition of CaMKII is concerned, the effects of MLT and compounds 3
and 4, in their racemic and homochiral forms, are shown in Table 3.
Interestingly, all of them exert inhibitory activities comparable to
that of MLT. Results obtained with the homochiral forms of these
two compounds revealed that, conceivably, the inhibition occurs
in a stereoselective manner since the enantiomers slightly differ
in potency, being the (S)-isomers the eutomers.
3. Discussion
We recently reported the synthesis of a series of chiral N-(phe-
noxyalkyl)amides that behave as melatonergic agonists with afﬁn-
ity towards MT1 and MT2 receptors in the range of nM.33 Some of
these compounds were studied in vitro as antioxidants. Surpris-
ingly, among the tested compounds, despite slight structural dif-
ferences, only compound 3 showed antioxidant activity being
slightly more active than MLT when tested in the DCFH-DA assay.
These results may allow us to rule out a possible interference of
MT1 and MT2 receptors on the antioxidant activity shown by 3,
since both compounds 3 and 4, which differ only for the acyl moi-Table 3
Inhibition of CaMKII activity by MLT and its analoguesa
Compounds IC50 ± SEM (lM)
MLT 128 ± 11
3 122 ± 28
(R)-3 129 ± 8
(S)-3 77 ± 14
4 107 ± 18
(R)-4 129 ± 8
(S)-4 117 ± 4
a CaM was used at 5 lM, values represent the mean of three independent
determinations.ety, are high afﬁnity melatonergic agonists. Interestingly, the anti-
oxidant activity of compound 3 occurs in a stereoselective manner,
since a signiﬁcant difference between its enantiomers was ob-
served; in particular the (R)-enantiomer behaves as the eutomer.
Conceivably, this result may suggest that the antioxidant activity
of 3 is speciﬁc; it should stem from the interaction with at least
one more macromolecular target involved in the pharmacological
outcome at the pharmacodynamic or pharmacokinetic level. Then,
in order to have a better insight on the mechanism of the antioxi-
dant capacity of compound 3 and its R-enantiomer, DPPH-free rad-
ical scavenging activity has been determined. From the results
appears evident that the antioxidant activity of compounds 3 and
(R)-3 is not accompanied by radical scavenging ability, since these
compounds, as well as MLT, showed only a weak DPPH inhibition
activity pattern. Thus, the antioxidant proﬁles of 3 and (R)-3 seem
to be similar to that of MLT, whose direct antioxidant activity is
only limited.39 Results on CaMKII inhibitory activity for our best
MT1/2 ligands (3 and 4) revealed that they share inhibitory proper-
ties with MLT. The inhibition occurs in a stereoselective manner,
the (S)-enantiomers being the eutomers. It is not possible to spec-
ulate whether there is a relationship between the results in the
antioxidant tests and on the CaMKII inhibition system. In fact,
compound 3 displayed modest stereoselectivity in the DCFH-DA
assay. The pattern of stereoselectivity—R > S—was opposite to that
observed in both CaMKII inhibition and MLT receptor binding
assays.4. Conclusions
The panel of selected in vitro assays allowed us to characterize a
MLT agonist, compound (R)-3, as an antioxidant, which proved to
be slightly more potent than MLT with a cytoprotective effect
against H2O2-induced cytotoxicity as high as that of MLT. While
being structurally speciﬁc, these activities should not pass through
MLT receptor activation. (R)-3 also inhibited in vitro CaMKII. Both
antioxidant and CaMKII inhibiting properties might prove beneﬁ-
cial to neurodegenerative disorders; indeed, ROS are considered
plausible targets for neurodegeneration prevention.38 Thus, it
should be very useful to obtain a MLT analogue that shows antiox-
idant capability and, at the same time inhibit CaMKII, since this is,
in turn, an important source of oxidative stress. Thus, (R)-3, which
presents these characteristics, should be a valid candidate for fur-
ther investigations in order to achieve new insights on possible
mechanism of action of this class of compounds.5. Experimental
5.1. Chemicals
Compounds 2–7 were reported previously by this group.33 MLT
is commercially available (Sigma–Aldrich, Milan, Italy).
5.2. Culture cells, H2O2-induced stress
Human hepatocellular liver carcinoma (HepG2) cells (Sigma–
Aldrich, St. Louis, MO) were cultured in DMEM-Dulbecco’s modi-
ﬁed Eagle’s medium (Sigma–Aldrich, St. Louis, MO) supplemented
with 10% inactivated fetal bovine serum (PAA Laboratories GmbH,
Pasching, Austria), L-glutamine (2 mM) (Sigma–Aldrich, St. Louis,
MO), penicillin (100 lg mL1) and streptomycin (100 lg mL1)
(Sigma–Aldrich, St. Louis, MO) and incubated at 37 C in a humid
atmosphere of 5% CO2. For experiments, the cells were grown to
70% conﬂuence, seeded for experiment and treated with H2O2 (Sig-
ma–Aldrich, St. Louis, MO) in serum free media for the indicated
times.
850 A. Carocci et al. / Bioorg. Med. Chem. 21 (2013) 847–8515.3. Cell viability assay
HepG2 cell viabilitywas assessed by using a conventional 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as-
say as previously reported.40–42 Brieﬂy, viable cells (104/well) were
plated into a sterile 96-Well Cell Culture Cluster (Corning, NY
14831) and, after removing themedium,were incubatedwith a ﬁnal
125 lM H2O2/well in DMEM for 10 min. Then cells were washed
twice with Phosphate Buffered Saline (PBS, Sigma–Aldrich, Milan,
Italy) and incubated for 2 h at 37 C in 5% CO2with different concen-
trations of test compounds. At the end of incubation, the culture
medium was replaced by a solution of MTT 0.5 mg/mL (Sigma–Al-
drich,Milan, Italy) in PBS. After 2 h incubation at 37 C in 5% CO2 this
solution was removed and 200 lL of DMSOwas added to each well.
Absorbance valuesweremeasured at 570 nmusing a Victor V3 plate
reader (PerkinElmer) and DMSO medium was used as blank solu-
tion. Results are expressed as the percentage of MTT reduction re-
spect to absorbance of control cells. All experiments were carried
out in sextuplicate and were repeated twice.
5.4. Dichloroﬂuorescein assay
Generation of ROS was monitored using an oxidation-sensitive
ﬂuorescent probe, 2070-dichlorodihydroﬂuorescein diacetate
(DCFH-DA, D6665; Sigma–Aldrich, St. Louis, MO) by slightly mod-
ifying the procedure reported by Wang and James.43 Brieﬂy, viable
HepG2 cells (104/well) were plated into a sterile black Culture
Plate™ 96F wells (PerkinElmer) 1 day before the experiments.
After removing the medium, the cells were incubated with a ﬁnal
125 lM H2O2/well in DMEM. After 10 min, cells were washed
twice with PBS, and incubated for 2 h at 37 C in 5% CO2 with dif-
ferent concentrations of test compounds. Medium was removed
and cells were incubated with ﬁnal 5 mM DCFH-DA in DMSO at
37 C in 5% CO2 in dark for an additional 30 min and then were
washed twice with PBS. The ﬂuorescence intensity was measured
directly in each well at an excitation wavelength of 485 ± 20 nm
and an emission wavelength of 530 ± 25 nm by multiwells ﬂuores-
cence Victor V3 plate reader (PerkinElmer). Each experiment was
performed three times in sextuplicate.
5.5. DPPH radical scavenging assay
The method of Blois44,45 was adopted. The assay was carried out
in 96-well microplates. Brieﬂy, a methanol DPPH solution
(100 lM) was mixed with different concentrations (0.1 mM,
1 mM, 5.5 mM) of test compounds and incubated for 20 min at
room temperature in the dark. After this time, 200 lL were placed
in a 96-well microplate and the absorbance of DPPH radical was
measured at 570 nm in a spectrometric plate reader (Victor D Per-
kin Elmer). All reaction mixtures were prepared in quadruplicate,
and at least three independent runs were performed for each sam-
ple. The antioxidant activity was determined as the RSA% (radical
scavenging activity), calculated as follows: RSA% = 100[(AoAi)/
Ao)  100, where Ao and Ai are the DPPH absorbance in absence
and in presence of added compound concentration i, respectively.
Data are expressed as means.
5.6. CaMKII activity assay
CaMKII activity was tested on Autocamtide in the presence of
the tested compounds. In a ﬁrst reaction step, active recombinant
full-length CaMKII (Signal Chem, La Jolla) was incubated for
30 min at 30 C with 1 mmol/L CaCl2 and 1 lmol/L CaM in 50 lL
of a reaction mixture (50 mmol/L HEPES pH 7.5, 10 mmol/L MgCl2,
0.5 mmol/L dithiothreitol (DTT), 100 nmol/L microcystin,
0.1 mmol/L non-radiolabeled ATP).46 In a second reaction step, a10 lL aliquot from the ﬁrst reaction was then incubated with
25 mM EGTA, 0.2 lCi/ll of Easy Tides Adenosine 50-triphosphate
[c32P]-ATP (Perkin Elmer) and 0.5 mM Autocamtide,47 in the pres-
ence of the tested compounds (at different concentrations) in order
to determine the effects of the compounds on CaMKII activity on its
substrate Autocamtide. AntCaNtide at a concentration of 5 lMwas
used as positive control of CaMKII inhibition. The reaction was car-
ried out for 30 min at 30 C, then 20 lL aliquots of the reaction
mixture were spotted onto Whatman P-81 phosphocellulose pa-
per. EGTA was added to quantify CaMKII autonomous activity.
Dried ﬁlters were counted on a Beckman LS 6000 scintillation
counter.
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